SCHEMBL9467302

SCHEMBL9467302

CC1(C)O[C@@H]2[C@H](O1)[C@@H](CO)O[C@H]2n1ccc(N)nc1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.63
MTOR P42345 2/20 0.63
THRB P10828 1/20 0.63
MDM2 Q00987 1/20 0.63
NCOA1 Q15788 1/20 0.63
NCOA3 Q9Y6Q9 1/20 0.63
PDE3A Q14432 3/20 0.54
PDE4D Q08499 1/20 0.54
SLC29A1 Q99808 1/20 0.54
PI4KA P42356 1/20 0.52
PI4K2B Q8TCG2 1/20 0.52
PI4K2A Q9BTU6 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
CACNA1F O60840 2/20 0.46
ALB P02768 2/20 0.46
MAPT P10636 2/20 0.46
CACNA1D Q01668 2/20 0.46
CACNA1S Q13698 2/20 0.46
CACNA1C Q13936 2/20 0.46
ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13003005 1.00 LMNA (0.63) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20668731 1.00 LMNA (0.63) LMNAMTORTHRBMDM2NCOA1
SCHEMBL26320640 1.00 LMNA (0.63) LMNAMTORTHRBMDM2NCOA1
SCHEMBL18671585 0.88 LMNA (0.60) LMNAMTORTHRBMDM2NCOA1
SCHEMBL4384095 0.86 LMNA (0.49) LMNAMTORTHRBMDM2NCOA1
SCHEMBL9755548 0.85 LMNA (0.72) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24829322 0.84 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL20668803 0.84 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL26320741 0.84 LMNA (0.46) LMNAMTORTHRBMDM2NCOA1
SCHEMBL24353169 0.83 LMNA (0.47) LMNAMTORTHRBMDM2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025389-A Phosphoramidate nucleoside drug compound, and synthetic method and drug application thereof 河南师范大学 2025-05-23 CN claimed
CN-118978559-A Synthesis method and medicinal application of phosphoramidate nucleoside prodrug 河南师范大学 2024-11-19 CN claimed
CN-120025389-A Phosphoramidate nucleoside drug compound, and synthetic method and drug application thereof 河南师范大学 2025-05-23 CN disclosed
CN-118978559-A Synthesis method and medicinal application of phosphoramidate nucleoside prodrug 河南师范大学 2024-11-19 CN disclosed
US-20240218008-A1 SYNTHESIS OF MOLNUPIRAVIR BY GREEN CHEMISTRY AMI LIFESCIENCES PRIVATE LIMITED (IN) 2024-07-04 US disclosed
US-20240218008-A1 SYNTHESIS OF MOLNUPIRAVIR BY GREEN CHEMISTRY AMI LIFESCIENCES PRIVATE LIMITED (IN) 2024-07-04 US disclosed
EP-3271468-B1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) 2022-12-14 EP disclosed
EP-3271468-B1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) 2022-12-14 EP disclosed
US-11407779-B1 Process for the preparation of molnupiravir DIVI'S LABORATORIES LTD. (IN) 2022-08-09 US disclosed
US-11312743-B1 Process for molnupiravir OPTIMUS DRUGS PRIVATE LIMITED (IN) 2022-04-26 US disclosed
US-20180066295-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) 2018-03-08 US disclosed
US-20180066295-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) 2018-03-08 US disclosed
US-20180066295-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) 2018-03-08 US disclosed
WO-2016146808-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A. (ES) 2016-09-22 WO disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218008-A1 SYNTHESIS OF MOLNUPIRAVIR BY GREEN CHEMISTRY TYMP, UMPS, TYMS LMNA 4377/4885MTOR 300/4885THRB 4799/4885
US-11407779-B1 Process for the preparation of molnupiravir ALKBH1, ALKBH5, ALKBH3 LMNA 2502/4885MTOR 2055/4885THRB 558/4885
US-11312743-B1 Process for molnupiravir SAMHD1, UMPS, NUDT1 LMNA 4110/4885MTOR 2259/4885THRB 4814/4885
US-20180066295-A1 DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES ADA, CDA, DCTD LMNA 3127/4885MTOR 4479/4885THRB 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.